Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187434 | 0.67 | IDO1 (0.33) | SRCIDO1 | |
| SCHEMBL25509177 | 0.67 | IDO1 (0.33) | SRCIDO1 | |
| SCHEMBL25187437 | 0.67 | IDO1 (0.33) | SRCIDO1 | |
| SCHEMBL2702083 | 0.65 | IDO1 (0.36) | IDO1 | |
| Hydrochloric Acid SCHEMBL28261308 | 0.64 | IDO1 (0.35) | IDO1 | |
| SCHEMBL2422312 | 0.62 | — | — | |
| Benzaldehyde SCHEMBL15288799 | 0.62 | ALDH1A1 (0.58) | TRIM24TRIM33 | |
| Trifluoromethanesulfonic Acid SCHEMBL19899442 | 0.62 | ALDH1A1 (0.47) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL37977 | 0.62 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL29181639 | 0.62 | PGK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2006102159-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA AND CANCER | YALE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | SRC 118/4885IDO1 1172/4885TRIM24 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.